La Jolla, CA15 Active Studies

Essential Tremor Clinical Trials in La Jolla, CA

Find 15 actively recruiting essential tremor clinical trials in La Jolla, CA. Connect with local research sites and explore new treatment options.

15
Active Trials
14
Sponsors
4,888
Enrolling

Recruiting Essential Tremor Studies in La Jolla

RecruitingLa Jolla, CANCT07076199

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The stu...

877 participants
Novo Nordisk A/S
View Study Details
RecruitingLa Jolla, CANCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingLa Jolla, CANCT06486441

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemot...

640 participants
Gilead Sciences
View Study Details
RecruitingLa Jolla, CANCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembroliz...

600 participants
AstraZeneca
View Study Details
RecruitingLa Jolla, CANCT06563895

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different orga...

582 participants
Eidos Therapeutics, a BridgeBio company
View Study Details
RecruitingLa Jolla, CANCT05548296

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer....

353 participants
Acrivon Therapeutics
View Study Details
RecruitingLa Jolla, CANCT06840496

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatme...

210 participants
Biomed Industries, Inc.
View Study Details
RecruitingLa Jolla, CANCT03550391

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to s...

206 participants
Canadian Cancer Trials Group
View Study Details
RecruitingLa Jolla, CANCT06741228

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage...

200 participants
Mind Medicine, Inc.
View Study Details
RecruitingLa Jolla, CANCT06388200

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mut...

150 participants
Ocugen
View Study Details
RecruitingLa Jolla, CANCT06334133

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus....

150 participants
vTv Therapeutics
View Study Details
RecruitingLa Jolla, CANCT06500481

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it ...

115 participants
NRG Oncology
View Study Details
RecruitingLa Jolla, CANCT06463028

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent end...

40 participants
Faeth Therapeutics
View Study Details
RecruitingLa Jolla, CANCT06152237

Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome. The...

20 participants
Taysha Gene Therapies, Inc.
View Study Details
RecruitingLa Jolla, CANCT05606614

Safety and Efficacy of TSHA-102 in Adolescent and Adult Females With Rett Syndrome (REVEAL Adult Study)

The REVEAL Adult Study is a multi-center, Phase 1/2 open-label, dose-escalation study of TSHA-102, an investigational gene therapy, in adult females with Rett syndrome. The safety, tolerability, and p...

18 participants
Taysha Gene Therapies, Inc.
View Study Details

About Essential Tremor Clinical Trials in La Jolla

Essential tremor is one of the most common movement disorders, causing involuntary shaking, most often in the hands. It is different from Parkinson's disease, though the two can be confused. Treatment includes medications, focused ultrasound, and deep brain stimulation for severe cases.

There are currently 15 essential tremor clinical trials recruiting participants in La Jolla, CA. These studies are seeking a combined 4,888 participants. Research is being sponsored by Novo Nordisk A/S, Immunocore Ltd, Gilead Sciences and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Essential Tremor Clinical Trials in La Jolla — FAQ

Are there essential tremor clinical trials in La Jolla?

Yes, there are 15 essential tremor clinical trials currently recruiting in La Jolla, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in La Jolla?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.

Are clinical trials in La Jolla free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.

What essential tremor treatments are being tested?

The 15 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for essential tremor.

Data updated March 2, 2026 from ClinicalTrials.gov